Canada approves generic Crestor
Mylan Pharmaceuticals ULC, the Canadian subsidiary of Mylan, has received approval from Health Canada for Mylan-rosuvastatin calcium tablets, 5mg, 10mg, 20mg and 40mg. Rosuvastatin is the generic version of AstraZeneca's Crestor tablets, which are used for the management of primary hypercholesterolemia, mixed dyslipidemia and familial hypercholesterolemia.

According to IMS Health, rosuvastatin calcium tablets, 5mg, 10mg, 20mg and 40mg, had Canadian sales of approximately $742 million for the 12 months ending Dec. 31, 2011. In Canada, generic drugs cost consumers an average of 60 percent less than their brand name counterparts, according to Pittsburgh-based Mylan.

Rosuvastatin is contraindicated in patients who are hypersensitive to it and in patients with active liver disease. Pregnant women or women wishing to become pregnant should not take rosuvastatin, as well as patients taking cyclosporine.